• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Baxter BioPharma Solutions

    PCI Pharma Services

    Emergent BioSolutions

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Adare Pharma Solutions

    PCI Pharma Services

    Cytovance Biologics

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Marketing Drugs & Devices in Massachusetts

    An Overview of the Commonwealth's new Code of Conduct

    Related CONTENT
    • Bioclinica Acquires Saliency
    • Monitoring Visit Reports for Medical Device Studies
    • Navigating Uncertainty: Considerations for Life Sciences 2021
    • Evonik Bolsters Excipients Portfolio
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    Gary C. Messplay and Colleen Heisey06.03.09
    Beginning July 1, 2009, pharmaceutical and medical device companies selling or marketing prescription drugs or medical devices to healthcare professionals licensed by the Commonwealth of Massachusetts must comply with the most stringent set of compliance-based, state-level laws to date, including a state-authored code of conduct. The regulations operate in three primary areas: establishing a code of conduct for product marketing by pharmaceutical and medical device companies; requiring these companies to train their employees regarding the regulations, to identify a compliance officer to the Commonwealth, and to report information to the Department of Public Health; and requiring company disclosure of financial interactions between the companies and certain healthcare providers.

    The regulations were developed pursuant to Chapter 111N, a component of Chapter 305, an Act to Promote Cost Containment, Transparency and Efficacy in the Delivery of Quality Healthcare, which was signed into law by Gov. Deval Patrick in August 2008 and became effective January 1, 2009. Since August 2008, the Massachusetts Department of Public Health has been working on implementing regulations, which has included seeking comments and feedback from the public and industry on proposed regulations.

    Massachusetts received comments on the draft regulations from a host of interests, including consumer advocacy groups, individual consumers, healthcare professionals, industry trade groups, charitable organizations, and pharmacy benefit managers and purchasers of drugs, devices, and biologics. While the final regulations were scaled back to accommodate some positions put forth by these groups, the final requirements remain stringent.

    In promulgating these rules, Massachusetts joins six other states and the District of Columbia in establishing obligations surrounding the marketing activities of pharmaceutical and/or medical device companies. California and Nevada mandate certain compliance requirements for both industries, but without disclosure obligations for medical device companies. Minnesota has prescribed government and public disclosure requirements for the pharmaceutical companies. Maine, Vermont, West Virginia, and the District of Columbia have also mandated disclosure to the government of certain information, although the requirements only affect the pharmaceutical industry. However, Massachusetts openly acknowledges that it believes its regulations are the strongest and most comprehensive in the nation to date, stating, "Massachusetts is the only state to require financial reporting by both pharmaceutical and medical device companies and to establish a state-authored marketing code of conduct restricting certain payment to healthcare practitioners."

    As provided in the final regulations, the intent of the regulations regarding "Pharmaceutical and Medical Device Manufacturer Conduct," (105 CMR 970.000) is "to benefit patients, enhance the practice of medicine, and ensure that the relationship between pharmaceutical or medical device manufacturers and healthcare practitioners not interfere with the independent judgment of healthcare practitioners." To that end, by July 1, a company covered by the regulations must adopt a marketing code of conduct consistent with standards established by Massachusetts, adopt and provide to the Commonwealth a description of the company's training program for educating sales and marketing staff about the code of conduct, certify to the Department of Public Health that the company complies with the Massachusetts code of conduct regulations to the best of the company's knowledge, information, and belief, adopt and provide to the Commonwealth a copy of the company's policies and procedures for investigating, correcting, and reporting on non-compliance with the code of conduct, and identify a compliance officer to the Department. The company must also certify to the Department that it has conducted annual audits to monitor compliance with the required code of conduct annually starting July 1, 2010.

    Pharmaceutical and medical device companies that employ or contract with a "pharmaceutical or medical device manufacturing agent" to sell or market prescription drugs or medical devices in the Commonwealth of Massachusetts to Massachusetts-licensed healthcare practitioners are subject to the regulations and must conform to the code of conduct requirements. A pharmaceutical or medical device manufacturing agent is defined as an employee or agent who "engages in detailing, promotional activities or other marketing of prescription drugs, biologics, or medical devices in the commonwealth to any physician, hospital, nursing home, pharmacist, health benefits plan administrator, other healthcare practitioner or person authorized to prescribe, dispense or purchase prescription drugs, biologics or medical devices."

    The marketing code of conduct sets forth the minimum standards for interactions between the industries of interest and healthcare providers, a term that specifically excludes hospitals and both full-time employees and individuals serving as board members of pharmaceutical or medical device manufacturers.

    While the Massachusetts code of conduct incorporates parts of the voluntary codes established by pharmaceutical and medical device industry groups - the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals and the Advanced Medical Technology Association (AdvaMed) Code of Ethics on Interactions with Healthcare Professionals, respectively - the regulations contain additional restrictions on interactions, including bans on some activities and limitations on others. In general, the code of conduct prohibits the pro-vision of entertainment or recreation activities and complimentary items by members of the industries to healthcare professionals, and places strict limitations on meals provided by industry to healthcare professionals licensed by Massachusetts. Notably:

    Meals: Companies may not provide or pay for meals for healthcare professionals: that are part of an entertainment or recreational event; that are not accompanied by an information presentation by the pharmaceutical or medical device company's agent; that are not conducted in the practitioner's office or a hospital setting, which includes hospitals, academic medical centers, or pharmaceutical or medical device company training facilities; and that include a healthcare practitioner's spouse or other guest. In addition, any meals must be modest and occasional in nature.

    Entertainment and Recreation: Companies are prohibited from providing entertainment or recreational items of any value to any healthcare practitioner who is not also a salaried employee of that company.

    Complimentary Items: Companies are prohibited from providing healthcare practitioners, either directly or indirectly, with any kind of payment, including cash or cash equivalents, equity, or tangible items, including "complimentary" items (e.g., pens, coffee mugs, gift cards), except where such payment is compensation for bona fide services. "Bona fide services" include an arrangement for services such as research, advisory board participation, and presentations at company-sponsored education and training, provided the arrangement is formalized in a written agreement, is specific to the services to be provided, is based on the fair market value of the services, and characterized by certain additional factors.

    Other Payments: Companies are prohibited from providing healthcare practitioners with any grants, scholarships, subsidies, support, consulting contracts, or educational or practice-related items in exchange for prescribing, disbursing, or using prescription drugs, biologics or medical devices or for a commitment to continue prescribing, disbursing, or using prescription drugs, biologics or medical devices.

    Continuing Medical Education (CME), Third-Party Scientific or Educational Conferences, or Professional Meetings: Companies are prohibited from providing financial support to cover or offset the travel or lodging costs, or other personal expenses of non-faculty healthcare practitioners attending a CME event, third-party scientific or educational conference or professional meeting and compensating for time spent by practitioners participating in any such event. Companies may not directly pay for practitioner meals at these events, although a CME provider or conference organizer may decide of its own volition to apply any financial support given by these companies to provide meals for all event participants. Additionally, any sponsorship of CME must meet the Accreditation Council for Continuing Medical Education (ACCME) Standards For Commercial Support, or the equivalent standards for commercial support maintained by the relevant continuing education accrediting body. Moreover, each company must separate its CME grant-making functions from its sales and marketing functions and must not provide advice or guidance to the CME provider regarding the content or faculty for company-funded CME.

    While these items and additional restrictions or prohibitions specified in the regulations are onerous, several activities by pharmaceutical and medical device companies are specifically permitted under the code of conduct. These include the dissemination of peer-reviewed information, advertising, sampling, provision of reasonable quantities of demonstration or evaluation units, payment for technical training and bona fide services (as described briefly above), price concessions provided in the ordinary course of business, reimbursement information, patient assistance programs, and charitable contributions. Each of these "permissible activities" is listed in the regulation and may be subject additional structural or functional limitations. Regardless of their enumerated status, each should be conducted in consideration of the overarching requirements of the code of conduct.

    A year after implementation of the regulations, companies will be required to disclose to the Department of Public Health, on an ongoing annual basis, certain information regarding payments made by companies in connection with sales and marketing activities of at least $50 provided to any covered recipient, including healthcare practitioners, pharmacists, and hospitals. Beginning July 1, 2010, companies must report the value, nature, purpose, and recipient of the payment in a disclosure report. The annual disclosure report includes a $2,000 fee (first paid July 1, 2009) to support administration of the program. Failure to comport with the regulations carries enforcement penalties. The Commonwealth is authorized to punish knowing and willful violations of the regulations with a fine of not more than $5,000 for each transaction, occurrence, or event.
    Gary C. Messplay is a partner in the Washington, D.C. office of Hunton & Williams LLP, where he is co-chair of the law firm's Food and Drug Practice. Colleen Heisey is an attorney in the firm's Food and Drug Practice.
    Related Searches
    • Manufacturing
    Suggested For You
    Bioclinica Acquires Saliency Bioclinica Acquires Saliency
    Monitoring Visit Reports for Medical Device Studies Monitoring Visit Reports for Medical Device Studies
    Navigating Uncertainty: Considerations for Life Sciences 2021 Navigating Uncertainty: Considerations for Life Sciences 2021
    Evonik Bolsters Excipients Portfolio Evonik Bolsters Excipients Portfolio
    Decentralized Trials Fuel AI Revolution in Clinical Research Decentralized Trials Fuel AI Revolution in Clinical Research
    Preparing to Adopt Intelligent Label Management Preparing to Adopt Intelligent Label Management
    LSNE Contract Manufacturing – The Recognized Leader in Lyophilization and Sterile Manufacturing LSNE Contract Manufacturing – The Recognized Leader in Lyophilization and Sterile Manufacturing
    Rondo-Pak Expands Capacity at Primary Facilities Rondo-Pak Expands Capacity at Primary Facilities
    New York City is Not Dead, Our Life Sciences Sector is Thriving New York City is Not Dead, Our Life Sciences Sector is Thriving
    Developments in Orphan Drug Exclusivity After Depomed Developments in Orphan Drug Exclusivity After Depomed
    NeoStem’s Irvine Site Receives Manufacturing License NeoStem’s Irvine Site Receives Manufacturing License
    cGMP Enforcement, the False Claims Act and Lessons From Omnicare cGMP Enforcement, the False Claims Act and Lessons From Omnicare
    New Rules on Medicinal Product Clinical Trials in Europe New Rules on Medicinal Product Clinical Trials in Europe
    New Compounding Legislation New Compounding Legislation
    Mobile Medical Apps Mobile Medical Apps

    Related FDA Watch

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20

    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20


    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20

    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20


    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19

    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19

    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19


    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19


    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19

    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • The Future Of Clinical Trials Series: Part I
    • Fujifilm To Invest $2B In US Manufacturing Site
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ingredient Manufacturers Discuss the E-Sports Market
    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Eitan Medical Receives FDA Clearance for Sapphire Infusion System
    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Flow Launches Collagen Waters
    Associations Congratulate Biden & Harris
    David Stanko Joins JPMS
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login